AccessibilityHelp
Immatics logo

Immatics(NASDAQ) IMTX

Market Cap$1.09BMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.
Since IPO (2018)-24%
5 Year-47%
1 Year-30%
1 Month-15%
Premium Feature
Moneyball Superscore
61/100
$7.16
-2.12%
-0.15Today
After hours$7.16+$0.00 (+0.00%)
Immatics last closing stock price
MetricPriceDate
Last closeUSD 7.152026-10-26
Immatics stock price return by period
PeriodPrice returnPrice at period startPeriod start date
1 week+1.42%USD 7.052026-10-19
1 month-14.58%USD 8.372026-09-25
3 month-18.15%USD 8.742026-07-28
Year to date-31.9%USD 10.502025-12-31
1 year-29.76%USD 10.182025-10-24
3 year-5.3%USD 7.552023-10-27
5 year-46.84%USD 13.452021-10-27
Since inception-23.85%USD 9.602018-12-12

Immatics Financials at a Glance

Market Cap

$1.09BMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Revenue (TTM)

€41.70M

Net Income (TTM)

-€206.55M

EPS (TTM)

-$1.85

P/E Ratio

-3.95

Dividend

$0.00

Beta (Volatility)

1.04 (Average)

Price

$7.16

Volume

756,066.688

Open

$7.55

Previous Close

$7.15

Daily Range

$7.03 - $7.73

52-Week Range

$6.65 - $12.41

Estimated Earnings Date

Nov 17, 2026

IMTX News

Scientists smiling and shaking hands

Why Immatics Stock Is Soaring Today

Keith SpeightsMay 2, 2023
GettyImages-943401146

Why Immatics Stock Is Soaring Today

Prosper Junior BakinyMar 17, 2021

IMTX: Motley Fool Moneyball Superscore

61

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About Immatics

Immatics N.V. is a clinical-stage biopharmaceutical firm focused on developing T-cell receptor (TCR) based immunotherapies for cancer treatment. The company specializes in targeted immunotherapies for solid tumors, utilizing innovative approaches such as adoptive cell therapies and antibody-like TCR Bispecifics.

Products and Services
  • ACTengine™ portfolio with candidates in Phase I clinical trials
  • Preclinical TCR Bispecifics targeting cancer testis antigens
  • Strategic partnerships with leading organizations for therapy development
Growth Outlook
  • Recent quarterly revenue of €9.14 million shows increasing interest in therapies
  • Strong cash position with €232 million in cash and short-term investments
  • Ongoing clinical trials may lead to significant advancements in cancer treatment
Financial Highlights
  • Trailing twelve months (TTM) revenue of €39.5 million indicates growth potential
  • Current ratio of 7.54 suggests strong liquidity and financial health
  • Net income for Q2 2026 was -€62.49 million, reflecting ongoing investment in R&D
Immatics N.V. is positioned in the biotechnology sector, focusing on innovative cancer therapies. The company's ACTengine™ portfolio includes several candidates currently in Phase I clinical trials, targeting various solid tumors. The strategic partnerships with major organizations enhance its development capabilities, potentially accelerating the path to market for its therapies. Recent financial data indicates a solid cash position, which supports ongoing research and development efforts. Despite reporting a net loss, the revenue growth and liquidity ratios suggest a promising outlook for future operations.
AI Generated • Oct 20, 2026

Industry

Biotechnology

Sector

Health Care

Employees

407

CEO

Harpreet Singh-Jasuja, PhD

Website

www.immatics.com

Headquarters

Tübingen, BW 72076, DE

IMTX Financials

Key Financial Metrics (TTM)

Gross Margin

100.00%

Operating Margin

-543.79%

Net Income Margin

-495.27%

Return on Equity

-47.04%

Return on Capital

-36.44%

Return on Assets

-42.54%

Earnings Yield

-25.32%

Dividend Yield

0.00%

Payout Ratio

0.00%

Stock Overview

Market Cap

$1.09BMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Shares Outstanding

149.64M

Volume

756.07K

Avg. Volume

750.35K

Financials (TTM)

Gross Profit

€41.70M

Operating Income

-€226.78M

EBITDA

-€193.84M

Operating Cash Flow

-€206.27M

Capital Expenditure

-€3.68M

Free Cash Flow

-€209.95M

Cash & ST Invst.

€393.19M

Total Debt

€14.60M

Immatics Performance Analysis

Immatics annual revenue and year-over-year revenue growth by fiscal year
Fiscal yearPeriod endRevenueYoY growth
20222022-12-31EUR 181,640,942342.1%
20232023-12-31EUR 58,376,999-67.9%
20242024-12-31EUR 168,565,279188.8%
20252025-12-31EUR 54,471,943-67.7%
Immatics sequential (quarter-over-quarter) revenue growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q32025-09-309.5%
Q42025-12-31281.0%
Q12026-03-31-61.5%
Q22026-06-3020.1%
Immatics annual diluted earnings per share and year-over-year EPS growth by fiscal year
Fiscal yearPeriod endDiluted EPSYoY growth
20222022-12-31EUR 0.57N/A
20232023-12-31EUR -1.27N/A
20242024-12-31EUR 0.15N/A
20252025-12-31EUR -1.81N/A
Immatics sequential (quarter-over-quarter) diluted earnings per share growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q32025-09-3027.6%
Q42025-12-3133.3%
Q12026-03-31-53.6%
Q22026-06-30-7.0%

Revenue Growth Rate

Annual and quarterly growth comparison

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name
Q2 2026YOY CHG

Revenue

€9.14M

+93.0%

Gross Profit

€9.14M

+93.0%

Gross Margin

100.00%

N/A

Market Cap

$1.09BMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

N/A

Market Cap/Employee

$1.55M

N/A

Employees

704

N/A

Net Income

-€62.49M

+11.2%

EBITDA

-€59.51M

+12.6%

Quarterly Fundamentals

Name
Q2 2026YOY CHG

Total Cash

€393.19M

-17.8%

Total Debt

€14.60M

-14.7%

Accounts Receivable

€6.66M

+128.8%

Inventory

€0.00

N/A

Long Term Debt

€11.94M

-15.4%

Short Term Debt

€2.66M

-11.3%

Return on Assets

-42.54%

N/A

Return on Invested Capital

-52.91%

N/A

Free Cash Flow

-€62.08M

-52.9%

Operating Cash Flow

-€61.20M

-56.7%

Other Investments to Explore

People Also Watch

Symbol / CompanyPricePrice Chg
JANXJanux Therapeutics, Inc.
$16.69+0.18%
IMCRImmunocore Holdings plc
$31.28+0.97%
ALLOAllogene Therapeutics, Inc.
$1.21-3.20%
LYELLyell Immunopharma, Inc.
$9.31-0.85%

Trending Stocks

Symbol / CompanyPricePrice Chg
NUNu Holdings
$12.59-16.95%
EWZiShares - iShares Msci Brazil ETF
$34.15-19.82%
ITUBItaú Unibanco
$7.70-20.37%
XPXP
$15.71-48.36%

Questions About IMTX

What is the current price of Immatics?

Immatics is trading at $7.15 per share.

What is the 52-week range for Immatics?

Over the past 52 weeks, Immatics has traded between $6.65 and $12.41.

How much debt does Immatics have?

As of the most recent reporting period, Immatics reported total debt of €16.70M.

How much cash does Immatics have on hand?

Immatics reported €265.77M in cash and cash equivalents in its most recent financial results.

What is Immatics’s dividend yield?

Immatics does not currently have a dividend yield.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.

View Premium Services